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ABSTRACT
Recently a range of ocular manifestations such as retinal and lens amyloid-
beta accumulation and retinal nerve fiber layer loss have been proposed as potential 
biomarkers in Alzheimer disease (AD). The TgCRND8 mouse model of AD exhibits 
age-dependent amyloid β (Aβ) oligomers accumulation and cognitive defects, amyloid 
plaques and hyperphosphorylated Tau deposition and inflammation. We proved the 
correlation between ocular pathologies and AD, observing increased levels of p-APP 
and p-Tau, accumulation of Aβ oligomers in the retina, eye, and optic nerve. The 
accumulation of amyloid markers was significantly stronger in the retinal ganglion 
cell (RGC) layer, suggesting that RGC might be more susceptible to degeneration. 
We detected a thinning of the RGC layer as well as RGC death in the retina of 
TgCRND8 mice, by using a combination of Optical Coherence Tomography (OCT), 
immunofluorescence, immunohistochemistry and Western blotting techniques. We 
proved for the first time the key role of C-Jun N-terminal Kinase (JNK) in the ocular 
degeneration. In support of this, the administration of the JNK inhibitor, D-JNKI1, 
was able to counteract the Aβ and p-Tau accumulation in the retina of TgCRND8 
mice, and consequently reduce RGCs loss. These results confirm that degenerative 
changes in the retina/eye of AD mouse model mirrors the events observed in the brain 
parenchyma. Ocular changes can be detected by non-invasive imaging techniques, 
such as OCT, to study and test different therapeutic strategies against degenerative 
events associated to AD.
INTRODUCTION
Alzheimer Disease (AD) is a chronic neurode-
generative disease that affects 20-40% of people older 
than 85 years with a relevant social and economic impact 
on society [1]. AD is characterized by the accumulation 
of protein aggregates in the brain parenchyma, leading 
to synaptic dysfunction, chronic inflammation and 
cognitive impairments [2-3]. Extracellular senile plaques 
are formed by aggregation of Aβ peptides, produced by 
the processing of the amyloid precursor protein (APP), 
while intracellular accumulation of Tau protein leads to 
the formation of neurofibrillary tangles (NFTs). Recently, 
accumulation of Aβ plaques and neurofibrillary tangles has 
been observed in the retina as well as in visual areas of the 
brain of AD patients [4]. Moreover, AD patients present 
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neuropathological alterations of the visual system and 
changes within ocular structures [5-7] at early stages of the 
disease. Interestingly, some visual pathological symptoms 
can precede the onset of dementia [8-9]; therefore, ocular 
scan could be used as a potential tool for AD diagnosis and 
also for monitoring AD progression [10-11].
The optical coherence tomography (OCT) is an in 
vivo non-invasive technique that provides cross-section 
imaging of the retina and allows to measure the retinal 
nerve fibers layer (RNFL). Using OCT, it has been shown 
that AD patients present significant thinning of the RNFL 
[12-15]. Currently, the most accredited hypothesis for 
ocular changes related to AD pathology suggests that the 
retinal ganglion cells (RGCs) die following accumulation 
of Aβ toxic species in the retina [5, 16-17], therefore 
leading to the thinning of the RNFL. To support this 
hypothesis, it has been shown that intra-vitreal injection 
of Aβ oligomers causes RGC damage [18-19].
In addition, several studies have described 
the association between AD and glaucoma. In fact, 
retinal disorders such as glaucoma are chronic 
neurodegenerative conditions, that affect retinal neurons 
leading to progressive and irreversible loss of vision 
in patients with AD [18, 20-21]. The manifestation of 
glaucoma is associated to an increase of intraocular 
pressure and an irreversible RGCs loss leading to a 
damage to the optic nerve [22]. Although glaucoma is 
not defined as an amyloidogenic disease, recently many 
animal and human studies highlighted the progressive 
accumulation of Aβ fragments in the retina [23] and 
its correlation to the increased intraocular pressure and 
RGCs apoptosis [23].
For these reasons, there is an expanding interest 
in the evaluation of the retina as a mirror of the CNS, 
particularly as a model to study AD pathology. In fact, a 
greater understanding of the link between ocular disorders 
and AD disease may help in the identification of some 
overlapping molecular mechanisms this will help in the 
development of novel therapeutic strategies, which are 
missing to date.
In this study we used a well-characterized murine 
model of AD, the TgCRND8 mouse model, to study 
retina/ocular pathological changes and ocular biomarkers 
for early detection of AD. We previously showed that 
TgCRND8 mice develop an early cognitive impairment, 
at 3 months of age, due to increasing Aβ oligomers 
production followed by phosphorylation of APP, as well 
as p-Tau deposition and inflammation [24-26]. Moreover, 
in these mice we showed that the JNK signaling pathway 
plays a key role in the pathogenesis of AD, and that the 
inhibition of JNK through D-JNKI1 exerts a protective 
effect if administrated at early and late stages of the 
disease [24-25].
To verify if JNK is implicated also in ocular 
degeneration, we focusing on RGCs death and ocular 
AD related-changes such as: Aβ oligomers accumulation, 
APP and Tau alterations, searching similar molecular 
mechanisms previously found in brain parenchyma [24]. 
Secondly, we analyzed the effect of D-JNKI1 against 
ocular pathological process in TgCRND8 mice.
We demonstrated that TgCRND8 mice present a 
significant thinning of the RNFL layers and a reduction 
in the number of RGCs in the retina. Moreover, we found 
in both the retina as well as the total eye homogenates 
an accumulation of Aβ 1-42 toxic species, p-APP and 
p-Tau, well-recapitulating the neuropathological changes 
observed in hippocampal and cortical brain regions 
[24]. In addition, TgCRND8 mice showed a powerful 
activation of the JNK signaling pathway in the retina, 
as previously demonstrated in hippocampal and cortical 
tissues, corroborating the hypothesis that the retina and the 
brain shared similar intracellular degenerative signaling 
pathways. Finally, D-JNKI1 treatment prevented AD-
related alterations in eye-homogenates and retinas, 
preserving the number of RGC and the thickness of the 
RNFL layer. These results indicate that eye represents an 
important window of the brain and can be used to monitor 
AD progression as well as efficacy of new treatments, 
being easily accessible with non-invasive optical imaging 
techniques as OCT.
RESULTS
TgCRND8 mice present accumulation of toxic 
Aβ species and tau in the retina as well as 
activation of the JNK signaling pathway
To detect typical hallmarks of AD, such as amyloid 
plaques and hyperphosphorylated Tau, we performed 
immunohistochemical analysis on the retina of TgCRND8 
(tg) and wild-type mice (WT). We observed an over-
expression of APP and Aβ oligomers in the retina of 
TgCRND8 by using respectively an antibody against 
APP and the 6E10 antibody to detect the beta amyloid 
deposition (Figure 1A-1D). We described for the first 
time a significant increase in the immuno-reactivity 
of APP in the Retinal Ganglion Cells (RGC layer), as 
well as a less marked APP staining in the inner nuclear 
layer (INL) (Figure 1A-1B) of 4-month-old TgCRND8 
compared to wild type mice. Using the 6E10 antibody, 
we observed a similar staining pattern (Figure 1C-1D). 
We then evaluated aggregates of hyperphosphorylated 
Tau (p-Tau) in the retina of TgCRND8 mice, observing 
for the first time a strongly increase of immune-positive 
staining of p-Tau compared to WT mice (Figure 1E-1F). 
The p-Tau immunoreactivity was strong in the RGC 
layer, and detectable at lower levels in the outer nuclear 
layer (ONL) and in the retinal pigment epithelium (RPE) 
(Figure 1E-1F). The evaluation of APP, p-APP, Tau and 
p-Tau levels was additionally performed and quantified 
Oncotarget3www.impactjournals.com/oncotarget
by Western blotting analysis. We found that the level of 
APP was increased by 5 folds in the retina of TgCRND8 
mice compared to WT mice (Figure 1G-1H), while the 
p-APP level was significantly increased by 1.5 folds 
(Figure 1G-1H, see quantification). In a similar manner, 
Tau and p-Tau were augmented by 1.5 folds in TgCRND8 
mice compared to wild type mice (Figure 1G, I see 
densitometric quantification). Moreover, we also detected 
Aβ toxic species in retina homogenates from TgCRND8 
mice, using the ELISA assay, underlyng a significant 
increase of Aβ oligomers formation in tg mice compared 
to WT mice (Figure 1L).
Since we proved that c-Jun N-terminal kinase 
(JNK) played a pivotal role in AD pathogenesis, being 
activated in cortical and hippocampal neurons at early 
stages of the disease [24-25, 27], we here investigated if 
similar activation of the JNK pathway was observed in 
the retina of TgCRND8 mice. We found that the p-JNK/
JNK ratio was significantly increased by 1.7 folds in 
retina homogenates from TgCRND8 vs WT mice (Figure 
2A-2B). To confirm the activation of the JNK pathway 
in TgCRND8 mice, we also measure the level of P-c-
Jun/c-Jun, the elective target of JNK. As shown in Figure 
2, the P-c-Jun/c-Jun ratio was increased by 2-folds in 
the retina of TgCRND8 mice compared to WT mice 
(Figure 2A-2C).
AD hallmarks can be detected in whole eye 
homogenate from TgCRND8
We investigated if changes detected in the retina 
of TgCRND8 mice could be also observed in whole 
eye homogenates, which are easier to handle in mice. 
As previously showed in the retina (Figure 1), in whole 
eye homogenates, the APP level increased by 5 folds 
in TgCRND8 compared to WT (p< 0.0001, Figure 3A-
Figure 1: Deposition and quantification of Aβ plaques, APP and hyperphosphorylated Tau in the retina of TgCRND8 
mice. Retinal flat mount indicating deposition of APP (A-B), 6e10 (C-D) positive amyloid aggregates, and P-Tau (E-F) in TgCRND8 mice 
[left] and WT mice [right] [Scale 200 μm]. (G-I) Western Blot analysis showed altered level of APP/P-APP, Tau/P-Tau [bands highlighted] 
in retinal lysates from Tg compared to WT animals and their densitometric quantification. (L) Quantitative determination of beta amyloid 
fragments [1-42] in the retina by ELISA assay, showing an increased in the level of Aβ 1–42 in TgCRND8 compared to control mice. Data 
are expressed as mean ±SEM, Student’s T-test *p< 0.05. Data are expressed as mean ±SEM. Student’s t-test: *p< 0.05, *** p< 0.001; n=6.
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3B), while p-APP increased by 2 folds (Figure 3A-3B). 
Similarly, Tau levels increased by 5 folds in TgCRND8 
(p< 0.05, Figure 3A-3C), while p-Tau was double in 
TgCRND8 mice compare to WT (p< 0.0001, Figure 3A-C). 
Coherently with the increased level of APP and Tau and 
their phosphorylated forms, the ELISA kit revealed an 
Figure 2: Detection of JNK signalling in the retina of TgCRND8 mice. (A) Western blot and (B-C) relative quantification 
showing P-JNK, JNK, P-c-Jun and c-Jun in retinal lysates from 4-month-old WT and TgCRND8 mice. P-JNK/JNK ratio and P-c-Jun/c-Jun 
ratio were increased in TgCRND8 mice if compared with the age-matched WT mice. Data are expressed as mean ±SEM. Student’s t-test, 
P-JNK/JNK: *** p< 0.001; P-c-Jun/c-Jun: *p< 0.05 [n=6].
Figure 3: Characterization of whole eye extracts in TgCRND8 mice. (A) Western Blot analysis and (B-C) their densitometric 
quantification showed an increase of APP, P-APP, Tau, P-Tau aggregation in whole eye extracts from Tg compared to WT animals. (D) 
Quantitative determination of beta amyloid fragments [1-40 and 1-42] in whole eye extracts by ELISA assay. A decrease in the level of Aβ 
1–40 fragments and an increase in the level of toxic Aβ 1–42 fragments was observed in TgCRND8 compared to control mice. Student’s 
t-test, *p< 0.05. Data are expressed as mean ±SEM. Student’s t-test: *p< 0.05, *** p< 0.001 [n=6].
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Figure 4: Characterization of JNK pathway in eye whole extract of TgCRND8 mice. (A) Western blot and (B-C) relative 
quantification showing P-JNK, JNK, P-c-Jun and c-Jun in whole extract of eye from 4-month-old WT and TgCRND8 mice. P-c-Jun/c-Jun 
and P-JNK/JNK ratio were increased in TgCRND8 mice if compared with the age-matched WT mice. Data are expressed as mean ±SEM. 
Student’s t-test, *p< 0.05, n=6.
Figure 5: Reduced NFL/GCL thickness and RGC numbers in the retina of TgCRND8 mice. The segmentation of retinal 
layers obtained by Optical coherence tomography (A) and the relative quantification (B) showed a reduction of the NFL/GCL thickness in 
TgCRND8 mice [right] compared to WT [left]. Student’s t-test, ** p< 0.01. (C-D) Retinal sections from Tg [right] and WT animals [left] 
stained with DAPI [Scale 20 μm]. (E-F) WT [Left] and TgCRND8 [Right] mice depicting retinal morphological changes in H&E staining. 
(G) Quantification of the RGC cell number showed a reduction of RGC cells in TgCRND8 compared to WT mice. Data were expressed as 
mean ±SEM. Mann-Whitney test, ** p< 0.01, n=6.
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increase in the level of Aβ 1-42 toxic species and a relative 
decreased of Aβ1-40 species in TgCRND8 if compared 
to WT total eye homogenates (p< 0.05, Figure 3, 3D). 
In the whole eye homogenate, the p-JNK/JNK as well as 
P-c-Jun/c-Jun ratios were double in TgCRND8 compared 
to WT (p< 0.05, Figure 4A-4C), confirming a powerful 
activation of the JNK signalling pathway.
The optical coherence tomography (OCT) allows 
the detection of structural changes in the retina 
of TgCRND8 mice
Using the OCT-technique, we observed structural 
alterations of the retinal layers in male TgCRND8 mice at 4 
months of age vs aged-matched WT mice. 
Figure 6: D-JNKI1 increases BRN3A and RGC numbers in retina of TgCRND8 mice. (A) Immunostaing of retinal sections 
performed with BRN3A [a specific marker for RGC nuclei] and (B) relative quantification showed an increase of the number of BRN3A+ 
cells in D-JNKI1 treated Tg vs untreated tg animals. Scale 20 μm. Student’s T-test: *p< 0.05; n=5. (C) Retinal sections and (D) correlated 
RGC quantification from D-JNKI1 treated Tg [in the top] and untreated mice [in the bottom] stained with H&E staining [Scale 200 μm]. 
Quantification of the RGC cell number showed an increase of RGC cells in D-JNKI1 treated TgCRND8 compared to untreated TgCRND8 
mice. Data are expressed as mean ±SEM. Mann-Whitney test, ** p< 0.01 [n=6].
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We found a significant thinning of Retinal 
Nerve Fiber Layer\Ganglion Cell Layer (RNFL\GCL) 
(19.58±0.94 vs 24.29±3.14 mean (μm) ±SD; p< 0.01) 
in TgCRND8 compared to WT mice (Figure 5A-5B), 
whereas the thickness of all the other retinal layers 
remained equal. 
We then verified if changes in the RNFL were 
due to loss of the RGCs, by performing DAPI staining 
(Figure 5C-5D) and Hematoxylin-Eosin histology 
(Figure 5E-5F) and counting the number of cells in the 
RGC layer (p< 0.01, Figure 5G). We found a 20% loss of 
RGCS in the retina of TgCRND8 mice, if compared to 
WT mice (Figure 5G) that can explain the significative 
thickness of the RNFL found (p< 0.01, Figure 5B). 
These results combined with previous evidence that AD 
markers strongly labeled the RGC layer (see Figure 1) 
supports the hypothesis that toxic species accumulate 
in the retina, and affect preferentially RGC, causing 
thinning of the RNFL.
D-JNKI1 treatment prevents loss of RGC and 
structural changes in the RNFL in TgCRND8 mice
TgCRND8 mice were chronically treated 
with the specific JNK inhibitor peptide D-JNKI1 by 
intraperitoneally injection as previously described [24-25] 
for 4/5 months (starting at 4 until 8 months of age). At 
the end of the treatment their retinas as well as the whole 
eyes and optic nerves were analyzed. In the retina, we 
performed RGCs count to determine if D-JNKI1 treatment 
was able to prevent their death, while in the whole eyes 
we tested the effect of D-JNKI1 on the biochemical AD 
markers.
Retinal sections were stained for brain-specific 
homeobox/POU domain protein 3A (BRN3A, a specific 
marker for RGC nuclei), and positive nuclei were counted. 
BRN3A positive cells were 15% higher in D-JNKI1 
treated TgCRND8 vs untreated TgCRND8 animals 
(23.40±5.15 vs 27.00±1.22, P=0,04; see Figure 6A-6B). 
Figure 7: D-JNKI1 decreases APP and P-Tau levels in whole eye extract of TgCRND8 mice. (A) Western Blot analysis and 
relative quantification (B) showed a decrease of APP, P-APP, (C) Tau and P-Tau in whole extract of eye from D-JNKI1 treated Tg animals 
compared to untreated tg animals. Also P-c-Jun/c-Jun and P-JNK/JNK ratio (D) were decreased in D-JNKI1 treated Tg vs untreated Tg 
mice. Student’s T-test: *p< 0.05; n=6].
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This result was also confirmed by using the Hematoxylin 
and Eosin histology. We proved that the number of RGC 
was increased by 34% in D-JNKI1-treated vs untreated 
TgCRND8 mice (Figure 6C-6D), confirming the 
neuroprotective effect of D-JNKI1 against AD-related 
ocular neuropathology.
We then tested the effect of D-JNKI1 against AD 
hallmarks by Western blotting analysis in whole eye 
homogenates. In TgCRND8 mice chronically treated with 
D-JNKI1, we found a significant decrease in both total and 
phosphorylated levels of APP and Tau (p< 0.0001, Figure 
7A-7B and Tau p< 0.0001, Figure 7A-7C). Furthermore, 
to investigate the D-JNKI1 impact on JNK pathway, we 
evaluated the P-c-Jun/c-Jun and p-JNK/JNK ratios in 
treated and untreated TgCRND8 and observed a significant 
decrease in the P-c-Jun/c-Jun ratio (equal to 40%) and 
p-JNK/JNK ratio (equal to 70%) (p< 0.05 Figure 7A-7D).
D-JNKI1 treatment prevents the optic nerve 
degeneration in TgCRND8 mice
Finally, we verified if treatment with D-JNKI1 
prevents the optic nerve degeneration observed in 
TgCRND8 mice. We performed Western blotting analysis 
on optic nerve homogenates, probing for p-APP/APP, 
p-Tau/Tau and p-JNK/JNK ratios in D-JNKI1 treated 
and untreated TgCRND8 mice. In accordance to the 
protective effect previously observed on RGCs, we found 
a significant decrease of p-APP/APP and p-Tau/Tau 
ratios in the optic nerve of D-JNKI1 treated vs untreated 
TgCRND8 mice (APP p< 0.001, Figure 8A-8B and 
Tau p< 0.01 Figure 8A-8C), due to inactivation of the 
JNK pathway. In fact, as expected, the level of p-JNK/
JNK were significantly decreased in D-JNKI1 treated 
TgCRND8 mice vs untreated (Figure 8D-8E). These 
results confirmed the protective role of D-JNKI1 against 
AD pathological manifestations.
DISCUSSION
Alzheimer disease (AD) is the most common form 
of dementia and to date no treatments are available to 
cure or slow AD progression. One explanation for the 
inefficiency of the therapeutic strategies is due to the fact 
that treatments start at later stages of AD, in the presence 
of irreversible brain damages (neuronal and synapse 
Figure 8: D-JNKI1 decreases P-APP/APP, P-Tau/Tau and P-JNK/JNK levels in the optic nerve of TgCRND8 mice. (A) 
Western Blot analysis and (B-C) relative quantification showed a decrease of P-APP/APP ratio and P-Tau/Tau ratio in the optic nerve from 
D-JNKI1 treated Tg animals compared to untreated tg animals. Student’s T-test: **p< 0.01; *** p< 0.001 n=5. (D) Western blot and (E) 
relative quantification showed a decrease of P-JNK/JNK ratio in the optic nerve of D-JNKI1 treated Tg compared to untreated tg animals. 
Data are expressed as mean ±SEM. Student’s T-test: *p< 0.05, *** p< 0.001 [n=6].
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loss). Therefore, it is important to understand and decode 
the cellular and molecular mechanisms underlying AD 
pathogenesis as well as find new methods to monitor 
the beginning and the progression of the pathological 
process. Recently, many efforts have been done to obtain 
early detection methods for the diagnosis of AD. New 
approaches in prevention trials include positron emission 
tomography (PET) studies of glucose metabolism 
combined with genetic risk assessment as well as use 
of biomarkers, such as measurements of beta-amyloid 
and tau levels in the cerebrospinal fluid [28]. However, 
these methods have been reported to be too expensive or 
invasive. Several evidences in the literature describe that 
many patients affected by AD report visual impairment 
[29-31], suggesting a correlation between ocular and AD 
pathologies [32-35]. In particular, a recent study proved 
that retinal thickness is decreased in both AD and mild 
cognitive impairment (MCI) patients compared to controls 
[36]. Importantly, these ocular defects can manifest before 
the onset of dementia [8, 9] and can be detected at early 
stages of AD by high resolution imaging technologies, 
such as optical coherence tomography (OCT). OCT is 
a non-invasive technique able to discriminate among 
different cellular populations into the retina and to 
quantify thinning of the retinal nerve fiber layer (associate 
to the loss of intra-retinal RGC axons). For these reasons, 
visual pathological symptoms can be used for early 
diagnosis of AD, as well as for monitoring the progression 
of the disease. To date, little is known about the link 
between visual impairments and AD and the nature of 
the visual systems alterations. Moreover, it is not clear if 
accumulation of Aβ peptides and Tau may occur in the eye 
and may be responsible for the structural changes observed 
in AD patients. Finally, the molecular mechanisms leading 
to retina thinning in AD patients are poorly understood. 
Investigating the cellular and molecular mechanisms 
leading to visual impairment in AD patients may allow 
the identification of new therapeutic targets that can be 
used for the treatment of visual alterations as well as in a 
more general view of brain dysfunction.
Therefore, the goal of this study was to: i) verify if 
murine models of AD present similar structural alterations 
of the visual system, focusing on TgCRND8 mice, a 
well characterized model of AD [24-27, 37]; ii) detect 
eventual accumulation of Aβ peptides or Tau in the eye 
of TgCRND8 mice; iii) study the molecular mechanisms 
leading to structural changes in the retina, focusing on 
JNK signalling pathway; iv) test the protective role of 
D-JNKI1, a specific JNK inhibitors, in the eye.
We found that TgCRND8 mice show ocular 
alterations, similar to the ones found in AD patients [11, 
38-39]. In fact, by using OCT, we observed in TgCRND8 
mice a substantial thinning of the retinal nerve fiber 
layer (RNFL) as well and a significant reduction of the 
RGC number counted by classical histological and 
immunohistochemical methods. Moreover, our results 
confirm, as previously described in the literature [32, 
40-47], that the reduction in the peri-papillary RNFL, 
detected by OCT, is due to RGC loss. To understand if 
the retinal degeneration in TgCRND8 mice mirrors AD-
related changes observed in the brain parenchyma (in 
particular hippocampus and cortex), we investigated the 
presence of amyloid and Tau deposition in the retina of 
TgCRND8 mice. We found that APP and p-APP levels 
were increased in the retina of TgCRND8 mice, followed 
by accumulation of Aβ1-42 toxic species, as previously 
observed in the brain parenchyma [24]. We also found a 
significant P-Tau deposition in the retina of TgCRND8 
animals by immunohistochemical and biochemical 
analyses, using three different specific antibodies to detect 
Tau protein and its hyperphosphorylated form. Consistent 
with these data, we found a similar increase in the level of 
APP, p-APP and p-Tau as well as accumulation of Aβ1-42 
oligomers in total eye homogenates. Our data are in line 
with those of Koronyo-Hamaoui et al. [48] that detected 
amyloid plaques in the retinal of APP/PS1 transgenic 
mice, another murine model of AD mouse model.
As in the brain parenchyma, where the level of 
Aβ oligomers, P-APP and P-Tau correlates with the 
severity of synaptic loss and memory deficits, in the 
retina, accumulation of Aβ oligomers, P-APP and P-Tau 
specifically in the RGC layer leads to RGC degeneration 
and consequently to thinning of the RNFL at early stages 
of the disease.
To understand the molecular mechanisms correlating 
Aβ accumulation and death of RGC, we analysed the 
activation of the JNK signally pathway in the retina of 
TgCRND8 mice. Many reports, including our work on 
TgCRND8 mice, have been shown that JNK is a key 
stress modulator, that is activated by Aβ oligomers and 
initiates the degenerative mechanisms affecting neurons 
in the brain.
Moreover, JNK pathway contributes to AD 
progression, being the main kinase responsible for APP 
[24-25, 27, 49] and Tau phosphorylation [26], therefore 
promoting their accumulation in the brain. Here we found 
that similar mechanisms applied for the retina. In fact, we 
reported activation of the JNK pathway and its selective 
target c-Jun in the retina of TgCRND8 mice. Our data 
support the hypothesis that in the retina of AD patients, as 
well as in the brain, an abnormal accumulation of Aβ toxic 
species and P-Tau leads to activation of the JNK pathway, 
which increases the production of these toxic species and 
leads to neuronal degeneration.
To prove that JNK activation is responsible for 
the loss of RGC and the thinning of the RNFL, we 
treated TgCRND8 mice with D-JNKI1, a powerful and 
specific JNK inhibitor. D-JNKI1 prevented the structural 
changes observed in TgCRND8 mice, by inhibiting 
the phosphorylation of APP and Tau as well as the 
accumulation of Aβ oligomers in the retina. In support of 
our hypothesis, other studies have correlated JNK activation 
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to RGC death in different models of retina degeneration, 
such as glaucoma, retina ischemia and excitotoxicity 
[50-53]. Moreover, the safety, tolerability, and the good 
systemic diffusion of D-JNKI1 in the treatment of post-
surgery or post-trauma intraocular inflammation have 
been already described [54]. These results reinforced the 
idea that treatment with D-JNKI1 is an innovative and 
potentially neuroprotective strategy against different ocular 
pathologies, including the ones related to AD.
Importantly, systemic application of D-JNKI1 
passed the first clinical trial phase and is well tolerated 
by patients; while it is in clinical trial phase III for the 
treatment of post-surgery or post-trauma intraocular 
inflammation [54].
In summary, our findings support the hypothesis 
that ocular pathological changes observed in AD models 
are predictive of the brain pathology. In fact, both 
ocular and brain neurodegeneration shared common 
pathological features (increased level of P-APP and P-Tau 
ad accumulation of Aβ oligomers), and degenerative 
mechanisms (JNK activation).
The availability of non-invasive imaging techniques 
(OCT), which are able to detect subtle, early changes at 
retinal level, opens a window for early detection of AD. 
As the retina cytology is much simple than that of the 
brain, this provided an excellent model to investigate 
the degenerative processes, signalling mechanisms, 
and to test novel neuroprotective agents. This similarity 
between the brain and the retina provides also an excellent 
experimental model for the examination of the efficacy 
of novel drugs as well as their pharmacokinetic and 
pharmacodynamics properties, offering several advantages 
in terms of cost, time, and analytical methods.
MATERIALS AND METHODS
Animals
In this study, we used TgCRND8 transgenic male 
mice. TgCRND8 mice expressed a mutant form of APP 695 
containing both the Swedish (KM670/671NL) and Indiana 
(V717F) mutations on a hybrid C3H/B6 genetic background 
and exhibit extensive amyloid deposition by 3 months of 
age [37]. Age matched wild-type male mice (129 SV) served 
as controls. Mice from Jackson Laboratories, USA, were 
bred at IRCCS Mario Negri Institute of Pharmacological 
Research in a specific pathogen free (SPF) facility with 
a regular 12:12 h light/dark cycle (lights on 07:00 a.m.), 
at a constant room temperature of 22 ± 2°C, and relative 
humidity approximately 55 ± 10%. Animals were housed 
[4 per group] in standard mouse cages, all with (hard wood 
shavings) as bedding material, ad libitum food (Global 
Diet 2018S, Harlan Italy) and water. No environmental 
enrichment was used because it tends to improve the signs 
of AD pathology in mouse models [55-56]. Procedures 
involving animals and their care were in accordance with 
national and international laws and policies. The Mario 
Negri Institute for Pharmacological Research (IRCCS, 
Milan, Italy) Animal Care and Use Committee (IACUC) 
approved all protocols, which were conducted according to 
the institutional guidelines, in compliance with Italian laws.
Animal treatment
All animals (Tg or WT) were intraperitoneally 
injected with vehicle (PBS) or D-JNKI1 (22 mg/kg) once 
a month from 4 to 8 months of age [57-58]. The weight 
of the animals was recorded before each treatment. Mice 
were treated always at the same time of the day (9:00–
10:00 A.M.) in a specific room inside the animal facility, 
following a randomized order. Each single mouse was our 
experimental unit. The description of D-JNKI1 structure 
was reported by Davoli et al., 2014 [59].
Optical coherence tomography (OCT)
In vivo analysis of the retina was performed using 
the Micron IV instrument combined with the Image-
Guided 830nm OCT (Phoenix Research Laboratories, 
Pleasanton, CA, USA).
Anesthesia was induced by intraperitoneal injection 
of 80 mg/kg Ketamine, 10 mg/kg Xylazine (Sigma-
Aldrich, Munich, Germany). To obtain mydriasis, a drop 
of tropicamide 0.5% (Visumidriatic, Tibilux Pharma, Italy) 
was instilled in each eye. The cornea was kept moist with 
an ophthalmic solution of hydroxyethylcellulose (Gel 
4000 2%; Bruschettini, Italy). The OCT pictures were 
acquired with a bidimensional scan (B-scan), performing 
a circular scan of 550 μm of diameter around the optic 
nerve head. For all animals, both eyes were examined and 
the results were averaged.
The segmentation of retinal layers was performed 
using Insight software (Phoenix Research Laboratories), 
and four types of measurements were conducted:
1) Nerve Fiber Layer/ Ganglion cell Layer (NFL/
GCL): from the inner limiting membrane to the limit 
between GCL and the Inner Plexiform Layer (IPL); 2) 
Inner Retinal Layers (IRL): from the IPL limit to the margin 
between the Inner Nuclear Layer (INL) and the Outer 
Plexiform Layer (OPL); 3) Outer Retinal Layers (ORL): 
from the INL/OPL margin to the external margin of the 
Outer Segment (OS) of the photoreceptors; 4) Total Retinal 
Thickness (RT): from the Nerve Fiber Layer/Ganglion cell 
Layer (NFL/GCL) to the external margin of the OS.
When performing OCT in mice it is quite difficult 
to discern between GCL and NFL [60]. To obviate to this 
problem these two layers were segmented together (GCL/
NFL).
Immunohistochemistry
After imaging, animals were sacrificed by cervical 
dislocation and eyes and optic nerves were harvested for 
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light microscopic evaluation, fixed in 4% (w/v) PFA, 
processed in an automatic tissue processor [Leica], and 
embedded in paraffin. Eye tissues were mounted and 
subjected to hematoxylin and eosin staining (Sigma-
Aldrich, see Fischer AH et al., 2008) [61]. Cell density 
in the GCL was determined for each eye by counting the 
number of cells in the middle part of retina over a distance 
of 300 μm (200 μm–500 μm from the edge of the optic 
disc). The thickness of inner plexiform layer was also 
evaluated and compared between WT and TGCRND8 
mice.
To detect the typical hallmarks of AD as Aβ plaques, 
hyperphosphorylated Tau and APP we used different 
primary antibodies: 6E10 (1:500, Covance, Emeryville, 
CA, USA), APP (cat. #2024170, 1:250, Millipore, 
Billerica, MA, USA) and AT100 (cat. #MN1060, 1:500, 
Euroclone). After deparaffinization, eyeballs sections (3 
μm thick; four slices per mouse) were unmasked with 
sodium citratePH 6 in the microwave for 2 minutes 
incubated for 1 h at room temperature with blocking 
solutions (6E10: 10% normal goat serum (NGS) plus 
0.3% Triton X-100; APP: 0.5% Triton X-100 plus 10% 
NGS; AT100: 0.3% Triton X-100 plus 10% NGS) and 
then overnight at 4°C with the primary antibodies. After 
incubation with the biotinylated secondary antibody 
(1:200; 1 h at room temperature; Vector Laboratories, 
Burlingame, CA, USA), the sections were incubated 
for 30 minutes at room temperature with the avidin-
biotin-peroxidase complex (Vector Laboratories) and 
diaminobenzidine (Sigma-Aldrich, Italy). Tissue analysis 
and image acquisition were done using an Olympus image 
analyzer and the Cell-R software.
Immunofluorescence analysis
After the sacrifice of the animals, the eyes were 
fixed in 4% PFA for 1h and then rinsed in PBS. Cornea 
and lens were removed and the retina, attached to the 
sclera, was incubated overnight in 30% sucrose before 
being embedded within optimal cutting temperature 
compound (Sigma, St. Louis, MO, USA).
Eyes were sectioned at a thickness of 12 μm and 
sections containing the optic disk were utilized for 
subsequent analysis. Sections were permeabilized with 
0.3%Triton X-100 and 2% BSA in PBS for 30 minutes 
at room temperature and blocked with 10% donkey 
serum for 30 minutes at room temperature. The primary 
antibody anti POU4F1/BRN3a (C-20) (sc-31984, Santa 
Cruz Biotechnology, CA, USA), was added and incubated 
overnight at 4°C (dilution 1:100). The following day, 
retinal sections were incubated with TRITC conjugated 
secondary antibodies (Jackson Immunoresearch, West 
Grove, PA, USA) diluted 1:50 in PBS for 1h. Nuclear 
staining was performed with DAPI (Sigma). Slides were 
mounted with Vectorshield medium (Vector Laboratories 
Inc, Burlingame, CA, USA). Omission of primary 
antibody was used as a staining control.
Positive cells were counted over a distance 
of 300 μm (250 μm–550 μm) from the center of the 
optic nerve head as previously described [62]. Four 
consecutive sections were analyzed. Images were 
acquired by epifluorescence microscopy using an Axio 
Plan 2 microscope and an MRc camera (Carl Zeiss, Jena, 
Germany). Identical exposure time was used for all the 
samples. Images measures and analysis were performed 
by ImageJ software.
Western blot
Protein concentrations were quantified using the 
Bradford Assay (Bio-Rad Protein Assay 500-0006, 
Munchen, Germany) 5 μg of TIF extracted proteins 
were separated by 10% SDS polyacrylamide gel 
electrophoresis. PVDF membranes were blocked in 
Tris-buffered saline (5% non fat milk powder, 0.1% 
Tween20, 1 h, room temperature). Primary antibodies 
were diluted in the same buffer (incubation overnight, 
4 °C) using: APP (cat. #2024170, 1:1000, Millipore, 
Billerica, MA, USA), p-APP (cat. #MABN10, 1:1000, 
Millipore, Billerica, MA, USA), anti Tau-5 (cat. 
#MABN162, 1:1000, Millipore Mab 361), p-Tau (cat. 
#MABN388, 1:1000, Millipore, Billerica, MA, USA), 
c-Jun (cat. #9165, 1:1000, Cell Signaling Technology, 
Danvers, MA, USA), p-c-Jun [Ser63] (cat. #9164, 
1:1000, Cell Signaling Technology, Danvers, MA, 
USA),p-JNK (cat. #9251, 1 : 1000, Cell Signaling 
Technology, Danvers, MA, USA), JNK (cat. #9252, 
1 : 1000, Cell Signaling Technology), anti-Actin 
(cat. #MAB1501, 1:5000, Millipore, Billerica, MA, 
USA) and at least six independent experiments were 
performed. Blots were developed using horseradish 
peroxidase-conjugated secondary antibodies (Santa 
Cruz Biotechnology) and the ECL chemiluminescence 
system (Promega). Western blots were quantified 
by densitometry using ImageQuant TL software 
(Amersham Biosciences, Amersham, UK) and was 
based on at least three independent experiments.
Quantification of Aβ 1-40 and Aβ 1-42
Eye balls and retinas from TG and WT mice were 
homogenized in a Tris buffer containing 50 mm Tris-HCl, 
ph 7.4, 150 mM NaCl, 50 mM EDTA, 1% Triton X-100, 
and 2% protease inhibitor. After centrifugation (15,000 
rpm, 21,000 × g, 4°C for 25 minutes), the supernatant was 
retained as the Triton-soluble fraction (soluble Aβ). The 
pellet was homogenized for a second time in the presence 
of 70% formic acid (FA) (10% v/w) and ultracentrifuged 
[55,000 rpm, 100,000 × g, 4°C, 1 h], and the resulting 
FA-extracted supernatant was neutralized with 1 M Tris 
buffer, pH 11, representing the FA-extracted insoluble 
fraction. Levels of Aβ
1–40
 and Aβ
1–42
 in each fraction 
were quantified by sandwich ELISA (IBL ELISA kit nr 
RE59721, RE59751).
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Statistical analysis
Statistical analysis was done using Graph Pad Prism 
6 program. WB data, ELISA data and neuronal counts 
were analyzed using two-way ANOVA, followed by 
Tukey’s post hoc test. All data were expressed as mean ± 
SEM with statistical significance given at p< 0.05.
Abbreviations
AD: Alzheimer’s disease; APP: amyloid 
precursor protein; CNS: central nervous system; NFTs: 
neurofibrillary tangles; JNK: c-Jun N-terminal kinase; 
INL: Inner Nuclear Layer; IPL: Inner Plexiform Layer; 
IRL: Inner Retinal Layers; OCT: Optical coherence 
tomography; ONL: Outer Nuclear Layer; OPL: Outer 
Plexiform Layer; ORL: Outer Retinal Layers; RGC: 
Retinal Ganglion cell; RNFL: retinal nerve fibers layer.
ACKNOWLEDGMENTS
The authors gratefully acknowledge J. Baggot for 
revised the English
CONFLICTS OF INTEREST
The authors declare no actual or potential conflicts 
of interest.
GRANT SUPPORT
This work was supported by ADDF (Alzheimer’s 
Drugs Discovery Foundation) USA grant to TB.
REFERENCES
1. Frost S, Martins RN, Kanagasingam Y Ocular biomarkers 
for early detection of Alzheimer’s disease. J Alzheimers Dis. 
2010; 22 1:1-16. https://doi.org/10.3233/JAD-2010-100819.
2. T. Wyss-Coray Inflammation in Alzheimer disease: driving 
force bystander or beneficial response? Nat. Med., 12 2006, 
pp. 1005–1015. Review.
3. V.B. Gupta, S.S. Indi, K.S. Rao Studies on the role of amino 
acid stereospecificity in amyloid beta aggregation J. Mol. 
Neurosci., 2008 34:35-43. PMID: 18157656.
4. Salobrar-Garcia E, Hoyas I, Leal M, de Hoz R, Rojas B, 
Ramirez AI, Salazar JJ, Yubero R, Gil P, Triviño A, Ramirez 
JM. Analysis of Retinal Peripapillary Segmentation in 
Early Alzheimer’s Disease Patients. Biomed Res Int. 2015; 
2015:636548. https://doi.org/10.1155/2015/636548.
5. Van Wijngaarden P, Hadoux X, Alwan M, Keel S, Dirani M. 
Emerging ocular biomarkers of Alzheimer disease. Clin Exp 
Ophthalmol. 2017 Jan; 45 : 54-61. https://doi.org/10.1111/
ceo.12872.
6. Reddy GB, Reddy PY, Surolia A. Alzheimer’s and Danish 
dementia peptides induce cataract and perturb retinal 
architecture in rats. Biomol Concepts. 2017 Mar 1; 8 : 
45-84. https://doi.org/10.1515/bmc-2016-0025.
7. Erskine D, Thomas AJ, Taylor JP, Savage MA, Attems J, 
McKeith IG, Morris CM, Khundakar AA. Neuronal Loss 
and Α-Synuclein Pathology in the Superior Colliculus and 
Its Relationship to Visual Hallucinations in Dementia with 
Lewy Bodies. Am J Geriatr Psychiatry. 2017 Jan 10. https://
doi.org/10.1016/j.jagp.2017.01.005.
8. Mentis MJ, Horwitz B, Grady CL, Alexander GE, VanMeter 
JW, Maisog JM, Pietrini P, Schapiro MB, Rapoport SI. 
Visual cortical dysfunction in Alzheimer’s disease evaluated 
with a temporally graded “stress test” during PET. Am J 
Psychiatry. 1996 Jan; 153: 32-40.
9. McKee AC, Au R, Cabral HJ, Kowall NW, Seshadri 
S, Kubilus CA, Drake J, Wolf PA. Visual association 
pathology in preclinical Alzheimer disease. J Neuropathol 
Exp Neurol. 2006 Jun; 65: 621-30.
10. Cunha LP, Lopes LC, Costa-Cunha LV, Costa CF, Pires 
LA, Almeida AL, Monteiro ML. Macular Thickness 
Measurements with Frequency Domain-OCT for 
Quantification of Retinal Neural Loss and its Correlation 
with Cognitive Impairment in Alzheimer’s Disease. PLoS 
One. 2016 Apr 22;11:e0153830. https://doi.org/10.1371/
journal.pone.0153830.
11. Garcia-Martin E, Bambo MP, Marques ML, Satue M, 
Otin S, Larrosa JM, Polo V, Pablo LE. Ganglion cell layer 
measurements correlate with disease severity in patients 
with Alzheimer’s disease. Acta Ophthalmol. 2016 Sep; 94: 
e454-9. https://doi.org/10.1111/aos.12977.
12. Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens 
CL. Retinal abnormalities in early Alzheimer’s disease. 
Invest Ophthalmol Vis Sci 2007; 48, 2285-2289.
13. Danesh-Meyer HV, Birch H, KuJ Y, Carroll S, Gamble G. 
Reduction of optic nerve fibers in patients with Alzheimer 
disease identified by laser imaging. Neurology 2006; 
67:1852–4.
14. Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve 
degeneration in Alzheimer’s disease. N Engl J Med 1986; 
315:485–7.
15. Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon 
J. Abnormal retinal thickness in patients with mild cognitive 
impairment and Alzheimer’s disease. Neurosci Lett 2007; 
420:97–9.
16. Chidlow G, Wood JP, Manavis J, Finnie J, Casson RJ. 
Investigations into Retinal Pathology in the Early Stages of 
a Mouse Model of Alzheimer’s Disease. J Alzheimers Dis. 
2017; 56:655-675. https://doi.org/10.3233/JAD-160823.
17. Joly S, Lamoureux S, Pernet V. Nonamyloidogenic 
processing of amyloid beta precursor protein is associated 
with retinal function improvement in aging male APP (swe)/
PS1ΔE9 mice. Neurobiol Aging. 2017 Feb 10. https://doi.
org/10.1016/j. neurobiolaging.2017.02.004.
Oncotarget13www.impactjournals.com/oncotarget
18. Gupta VK, Chitranshi N, Gupta VB, Golzan M, Dheer 
Y, Wall RV, Georgevsky D, King AE, Vickers JC, Chung 
R, Graham S. Amyloid β accumulation and inner retinal 
degenerative changes in Alzheimer’s disease transgenic 
mouse. Neurosci Lett. 2016 Jun 3; 623:52-6. https://doi.
org/10.1016/j.neulet.2016.04.059.
19. Golzan SM, Goozee K, Georgevsky D, Avolio A, Chatterjee 
P, Shen K, Gupta V, Chung R, Savage G, Orr CF, Martins 
RN, Graham SL. Retinal vascular and structural changes are 
associated with amyloid burden in the elderly: ophthalmic 
biomarkers of preclinical Alzheimer’s disease. Alzheimers 
Res Ther. 2017 Mar 1;9:13. https://doi.org/10.1186/
s13195-017-0239-9.
20. Wostyn P, De Groot V, Van Dam D, Audenaert K, Killer HE, 
De Deyn PP. Age-related macular degeneration, glaucoma 
and Alzheimer’s disease: amyloidogenic diseases with the 
same glymphatic background? Cell Mol Life Sci. 2016 Nov; 
73:4299-4301. https://doi.org/10.1007/s00018-016-2348-1
21. Chiasseu M, Cueva Vargas JL, Destroismaisons L, Vande 
Velde C, Leclerc N, Di Polo A. Tau Accumulation, 
Altered Phosphorylation, and Missorting Promote 
Neurodegeneration in Glaucoma. J Neurosci. 2016 
May 25; 36: 5785-98. https://doi.org/10.1523/
JNEUROSCI.3986-15.2016.
22. Casson RJ, Chidlow G, Wood JP, Crowston JG, Goldberg I. 
Definition of glaucoma: clinical and experimental concepts. 
Clin Exp Ophthalmol 2012; 40:341–349. https://doi.org/10.
1111/j.1442-9071.2012.02773.
23. Gupta V, You Y, Li J, Gupta V, Golzan M, Klistorner 
A, van den Buuse M, Graham S. BDNF impairment is 
associated with age-related changes in the inner retina and 
exacerbates experimental glaucoma. Biochim Biophys 
Acta 2014; 1842:1567–1578. https://doi.org/10.1016/j.
bbadis.2014.05.026.
24. Sclip A, Antoniou X, Colombo A, Camici GG, Pozzi L, 
Cardinetti D, Feligioni M, Veglianese P, Bahlmann FH, 
Cervo L, Balducci C, Costa C, Tozzi A, Calabresi P, Forloni 
G, Borsello T. c-Jun N-terminal kinase regulates soluble Aβ 
oligomers and cognitive impairment in AD mouse model. J 
Biol Chem. 2011; 286 : 43871-80. https://doi.org/10.1074/
jbc.M111.297515.
25. Sclip A, Tozzi A, Abaza A, Cardinetti D, Colombo I, 
Calabresi P, Salmona M, Welker E, Borsello T. c-Jun 
N-terminal kinase has a key role in Alzheimer disease 
synaptic dysfunction in vivo. Cell Death Dis. 2014; 23;5: 
e1019. https://doi.org/10.1038/cddis.2013.559.
26. Ploia C, Antoniou X, Sclip A, Grande V, Cardinetti 
D, Colombo A, Canu N, Benussi L, Ghidoni R, 
Forloni G, Borsello T. JNK plays a key role in tau 
hyperphosphorylation in Alzheimer’s disease models. J 
Alzheimers Dis. 2011;26:315-29. https://doi.org/10.3233/
JAD-2011-110320.
27. Sclip A, Arnaboldi A, Colombo I, Veglianese P, Colombo 
L, Messa M, Mancini S, Cimini S, Morelli F, Antoniou X, 
Welker E, Salmona M, Borsello T. Soluble Aβ oligomer-
induced synaptopathy: c-Jun N-terminal kinase’s role. J Mol 
Cell Biol. 2013 Aug; 5: 277-9. https://doi.org/10.1093/jmcb/
mjt015.
28. Jack CR, Holtzman DM. Biomarker modeling of 
Alzheimer’s disease. Neuron 2013; 80:1347–58. https://doi.
org/10.1016/j.neuron.2013.12.003.
29. Schlotterer G, Moscovitch M., Crapper-McLachlan D. 
Visual processing deficits as assessed by spatial frequency 
contrast sensitivity and backward masking in normal ageing 
and Alzheimer’s disease. Brain 1984; 107, 309–325.
30. Sadun AA, Borchert M, Devita E, Hinton DR, Bassi 
CJ. Assessment of visual impairment in patients with 
Alzheimer’s disease. Am. J. Ophthalmol. 1987; 104, 
113–120.
31. Cronin-Golomb A, Sugiura R, Corkin S, Growdon 
JH. Incomplete achromatopsia in Alzheimer’s disease. 
Neurobiol. Aging 1993; 14, 471–477.
32. Gunes¸ A, Demirci S, Tok L, Tok O, Demirci S. Evaluation 
of retinal nerve fiber layer thickness in Alzheimer disease 
using spectraldomain optical coherence tomography. Turk 
J Med Sci 2015; 45:1094–7.
33. Cheung CY, Ikram MK, Chen C, Wong TY. Imaging 
retina to study dementia and stroke. Prog Retin Eye 
Res. 2017 Mar; 57:89-107. https://doi.org/10.1016/j.
preteyeres.2017.01.001.
34. Jones-Odeh E, Hammond CJ. How strong is the relationship 
between glaucoma, the retinal nerve fibre layer, and 
neurodegenerative diseases such as Alzheimer’s disease 
and multiple sclerosis? Eye (Lond). 2015 Oct; 29:1270-84. 
https://doi.org/10.1038/eye.2015.158.
35. Antoniades CA, Kennard C. Oculomotor abnormalities in 
posterior cortical atrophy: are they different from those in 
Alzheimer’s disease after all? Brain. 2015 Jul; 138:1773-5. 
https://doi.org/10.1093/brain/awv124.
36. Den Haan J, Verbraak FD, Visser PJ, Bouwman FH. Retinal 
thickness in Alzheimer’s disease: A systematic review 
and meta-analysis. Alzheimers Dement (Amst). 2017 Jan 
25;6:162-170. https://doi.org/10.1016/j.dadm.2016.12.014.
37. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, 
Pearson J, Strome R, Zuker N, Loukides J, French J, Turner 
S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, 
Gervais F, Bergeron C, Fraser PE, Carlson GA, George-
Hyslop PS, Westaway D. Early-onset amyloid deposition 
and cognitive deficits in transgenic mice expressing a 
double mutant form of amyloid precursor protein 695. J 
Biol Chem. 2001 Jun 15;276:21562-70.
38. Ghiso JA, Doudevski I, Ritch R, Rostagno AA. Alzheimer’s 
disease and glaucoma: mechanistic similarities and 
differences. J Glaucoma. 2013 Jun-Jul; 22:S36-8. https://
doi.org/10.1097/IJG.0b013e3182934af6.
39. Dehabadi MH, Davis BM, Wong TK, Cordeiro MF. Retinal 
manifestations of Alzheimer’s disease. Neurodegener Dis 
Manag. 2014;4:241-52. https://doi.org/10.2217/nmt.14.19.
Oncotarget14www.impactjournals.com/oncotarget
40. Pillai JA, Bermel R, Bonner-Jackson A, Rae-Grant A, 
Fernandez H,Bena J, et al. Retinal nerve fiber layer 
thinning in Alzheimer’s disease: a case-control study in 
comparison to normal aging, Parkinson’s disease, and non-
Alzheimer’s dementia. Am J Alzheimers Dis Other Demen 
2016;31:430–6.
41. La Morgia C, Ross-Cisneros FN, Koronyo Y, Hannibal J, 
Gallassi R, Cantalupo G, Sambati L, Pan BX, Tozer KR, 
Barboni P, Provini F, Avanzini P, Carbonelli M, Pelosi 
A, Chui H, Liguori R, Baruzzi A, Koronyo-Hamaoui M, 
Sadun AA, Carelli V. Melanopsin retinal ganglion cell loss 
in Alzheimer disease. Ann Neurol. 2016 Jan;79:90-109.
42. Shariflou S, Georgevsky D, Mansour H, Rezaeian M, Hosseini 
N, Gani F, Gupta V, Braidy N, Golzan SM. Diagnostic and 
prognostic potential of retinal biomarkers in early on-set 
Alzheimer`s disease. Curr Alzheimer Res. 2017 Mar 29. 
https://doi.org/10.2174/1567205014666170329114445.
43. Eraslan M, Çerman E, Çekiç O, Balci S, Dericioğlu V, Sahin 
Ö, Süer D, Chabou B, Tuncer Elmaci EN. Neurodegeneration 
in ocular and central nervous systems: optical coherence 
tomography study in normal-tension glaucoma and 
Alzheimer disease. Turk J Med Sci. 2015; 45:1106-14
44. Lu Y, Li Z, Zhang X, Ming B, Jia J, Wang R, Ma D. 
Retinal nerve fiber layer structure abnormalities in early 
Alzheimer’s disease: evidence in optical coherence 
tomography. Neurosci Lett. 2010 Aug 9; 480:69-72. https://
doi.org/10.1016/j.neulet.2010.06.006.
45. Kesler A, Vakhapova V, Korczyn AD, Naftaliev E, 
Neudorfer M. Retinal thickness in patients with mild 
cognitive impairment and Alzheimer’s disease. Clin. 
Neurol. Neurosurg. 2011; 113, 523–526. https://doi.
org/10.1016/j.clineuro.2011.02.014.
46. Kirbas S, Turkyilmaz K, Anlar O, Tufekci A, Durmus 
M. Retinal nerve fiber layer thickness in patients with 
Alzheimer disease. J. Neuroophthalmol. 2013; 33, 58–61. 
https://doi.org/10.1097/WNO.0b013e318267fd5f.
47. Cheung CY, Ong YT, Hilal S, Ikram MK, Low S, Ong 
YL, Venketasubramanian N, Yap P, Seow D, Chen CL, 
Wong TY. Retinal ganglion cell analysis using high-
definition optical coherence tomography in patients with 
mild cognitive impairment and Alzheimer’s disease. J 
Alzheimers Dis. 2015;45:45-56. https://doi.org/10.3233/
JAD-141659.
48. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, 
Ko MK, Black KL, Schwartz M, Farkas DL. Identification 
of amyloid plaques in retinas from Alzheimer’s patients and 
noninvasive in vivo optical imaging of retinal plaques in a 
mouse model. Neuroimage. 2011 Jan;54:S204-17. https://
doi.org/10.1016/j.neuroimage.2010.06.020.
49. Colombo A, Bastone A, Ploia C, Sclip A, Salmona M, 
Forloni G, Borsello T. JNK regulates APP cleavage and 
degradation in a model of Alzheimer’s disease. Neurobiol 
Dis. 2009 Mar;33:518-25. https://doi.org/10.1016/j.
nbd.2008.12.014.
50. Bessero AC, Chiodini F, Rungger-Brändle E, Bonny C, 
Clarke PG. Role of the c-Jun N-terminal kinase pathway 
in retinal excitotoxicity, and neuroprotection by its 
inhibition. J Neurochem. 2010 Jun;113:1307-18. https://
doi.org/10.1111/j.1471-4159.2010.06705.x.
51. Sun H, Wang Y, Pang IH, Shen J, Tang X, Li Y, Liu C, Li B. 
Protective effect of a JNK inhibitor against retinal ganglion 
cell loss induced by acute moderate ocular hypertension. 
Mol Vis. 2011 Apr 6;17:864-75.
52. Fernandes KA, Harder JM, Fornarola LB, Freeman RS, 
Clark AF, Pang IH, John SW, Libby RT. JNK2 and JNK3 
are major regulators of axonal injury-induced retinal 
ganglion cell death. Neurobiol Dis. 2012 May; 46:393-401. 
https://doi.org/10.1016/j.nbd.2012.02.003.
53. Dvoriantchikova G, Ivanov D. Tumor necrosis factor-
alpha mediates activation of NF-κB and JNK signaling 
cascades in retinal ganglion cells and astrocytes in opposite 
ways. Eur J Neurosci. 2014 Oct;40:3171-8. https://doi.
org/10.1111/ejn.12710.
54. Beydoun T, Deloche C, Perino J, Kirwan BA, Combette 
JM, Behar-Cohen F. Subconjunctival injection of XG-102, 
a JNK inhibitor peptide, in patients with intraocular 
inflammation: a safety and tolerability study. J Ocul 
Pharmacol Ther. 2015 Mar;31:93-9. https://doi.org/10.1089/
jop.2013.0247.
55. Valero J, España J, Parra-Damas A, Martín E, Rodríguez-
Álvarez J, Saura CA. Short-term environmental enrichment 
rescues adult neurogenesis and memory deficits in APP 
(Sw,Ind) transgenic mice. PLoS One. 2011 Feb 9;6:e16832. 
https://doi.org/10.1371/journal.pone.0016832.
56. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-
Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, 
Sisodia SS. Environmental enrichment reduces Abeta levels 
and amyloid deposition in transgenic mice. Cell. 2005 Mar 
11;120:701-13. https://doi.org/10.1016/j.cell.2005.01.015
57. Borsello T, Clarke PG, Hirt L, Vercelli A, Repici M, 
Schorderet DF, Bogousslavsky J, Bonny C. A peptide 
inhibitor of c-Jun N-terminal kinase protects against 
excitotoxicity and cerebral ischemia. Nat Med. 2003 
Sep;9:1180-6.
58. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. 
Cell-permeable peptide inhibitors of JNK: novel blockers 
of beta-cell death. Diabetes. 2001 Jan;50:77-82.
59. Davoli E, Sclip A, Cecchi M, Cimini S, Carrà A, Salmona 
M, Borsello T. Determination of tissue levels of a 
neuroprotectant drug: the cell permeable JNK inhibitor 
peptide. J Pharmacol Toxicol Methods. 2014 Jul-Aug; 
70:55-61. https://doi.org/10.1016/j.vascn.2014.04.001.
60. Sohn EH, van Dijk HW, Jiao C, Kok PH, Jeong W, 
Demirkaya N, Garmager A, Wit F, Kucukevcilioglu M, 
van Velthoven ME, DeVries JH, Mullins RF, Kuehn MH, 
Schlingemann RO, Sonka M, Verbraak FD, Abràmoff MD. 
Retinal neurodegeneration may precede microvascular 
changes characteristic of diabetic retinopathy in diabetes 
Oncotarget15www.impactjournals.com/oncotarget
mellitus. Proc Natl Acad Sci U S A. 2016 May 10; 113: 
E2655-64. https://doi.org/10.1073/pnas.1522014113.
61. Fischer AH, Jacobson KA, Rose J, Zeller R. Hematoxylin 
and eosin staining of tissue and cell sections. CSH Protoc. 
2008 May 1;2008. https://doi.org/10.1101/pdb.prot4986.
62. Mead B, Thompson A, Scheven BA, Logan A, Berry M, 
Leadbeater W. Comparative evaluation of methods for 
estimating retinal ganglion cell loss in retinal sections and 
wholemounts. PLoS One. 2014 Oct 24; 9:e110612. https://
doi.org/10.1371/journal.pone.0110612.
